BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 11596199)

  • 1. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
    Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
    Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
    Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
    Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes.
    Vincent-Viry M; Pontes ZB; Gueguen R; Galteau MM; Siest G
    Genet Epidemiol; 1994; 11(2):115-29. PubMed ID: 8013893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans.
    Tsutsumi K; Kotegawa T; Matsuki S; Tanaka Y; Ishii Y; Kodama Y; Kuranari M; Miyakawa I; Nakano S
    Clin Pharmacol Ther; 2001 Aug; 70(2):121-5. PubMed ID: 11503005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
    Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of Tibetan medicine zuotai on the activity, protein and mRNA expression of CYP1A2 and NAT2].
    Li XY; Liu YN; Li YP; Zhu JB; Yao XC; Li YF; Yang M; Yuan M; Fan XR; Yin YM
    Yao Xue Xue Bao; 2014 Feb; 49(2):267-72. PubMed ID: 24761621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities.
    Fuchs P; Haefeli WE; Ledermann HR; Wenk M
    Eur J Clin Pharmacol; 1999 Jan; 54(11):869-76. PubMed ID: 10027663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HPLC determination of five caffeine metabolites].
    Lu JF; Yi T; Cao XM; Zhuo HT; Lin SS
    Yao Xue Xue Bao; 1997 Aug; 32(8):607-11. PubMed ID: 11596311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.
    Relling MV; Lin JS; Ayers GD; Evans WE
    Clin Pharmacol Ther; 1992 Dec; 52(6):643-58. PubMed ID: 1458773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.
    Krul C; Hageman G
    J Chromatogr B Biomed Sci Appl; 1998 May; 709(1):27-34. PubMed ID: 9653923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthine oxidase activity assessment.
    Nyéki A; Biollaz J; Kesselring UW; Décosterd LA
    J Chromatogr B Biomed Sci Appl; 2001 May; 755(1-2):73-84. PubMed ID: 11393735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.
    Nyéki A; Buclin T; Biollaz J; Decosterd LA
    Br J Clin Pharmacol; 2003 Jan; 55(1):62-7. PubMed ID: 12534641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
    McQuilkin SH; Nierenberg DW; Bresnick E
    Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?
    Jetter A; Kinzig M; Rodamer M; Tomalik-Scharte D; Sörgel F; Fuhr U
    Eur J Clin Pharmacol; 2009 Apr; 65(4):411-7. PubMed ID: 19082994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determination of the activity of cytochrome P-450 CYP2A6 by HPLC method with caffeine as metabolizing probe].
    Li J; Peng XQ; Zhang J; Xu JP
    Yao Xue Xue Bao; 2006 Mar; 41(3):282-4. PubMed ID: 16759004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
    Hakooz NM
    Curr Drug Metab; 2009 May; 10(4):329-38. PubMed ID: 19519341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caffeine metabolism before and after liver transplantation.
    Bechtel YC; Lelouët H; Hrusovsky S; Brientini MP; Mantion G; Paintaud G; Miguet JP; Bechtel PR
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):53-60. PubMed ID: 11270802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.
    Jetter A; Kinzig-Schippers M; Illauer M; Hermann R; Erb K; Borlak J; Wolf H; Smith G; Cascorbi I; Sörgel F; Fuhr U
    Eur J Clin Pharmacol; 2004 Mar; 60(1):17-21. PubMed ID: 14747882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary effects of Sideritis scardica "mountain tea" on human in vivo activities of xenobiotic metabolizing enzymes in healthy subjects.
    Begas E; Kilindris T; Kouvaras E; Tsioutsioumi A; Kouretas D; Asprodini EK
    Food Chem Toxicol; 2018 Dec; 122():38-48. PubMed ID: 30266316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping.
    Kashuba AD; Bertino JS; Kearns GL; Leeder JS; James AW; Gotschall R; Nafziger AN
    Clin Pharmacol Ther; 1998 May; 63(5):540-51. PubMed ID: 9630827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.